Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,084,866
  • Shares Outstanding, K 17,308
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,890 K
  • 60-Month Beta 1.19
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.32
  • Number of Estimates 3
  • High Estimate -0.29
  • Low Estimate -0.35
  • Prior Year -0.28
  • Growth Rate Est. (year over year) -14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.96 +50.36%
on 11/11/19
66.50 -5.13%
on 12/09/19
+20.53 (+48.24%)
since 11/08/19
3-Month
31.89 +97.84%
on 10/02/19
66.50 -5.13%
on 12/09/19
+17.13 (+37.27%)
since 09/10/19
52-Week
16.82 +275.09%
on 12/26/18
66.50 -5.13%
on 12/09/19
+39.66 (+169.27%)
since 12/10/18

Most Recent Stories

More News
Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).

KRYS : 63.09 (+0.65%)
Krystal Biotech to Present at the Piper Jaffray 31st Annual Healthcare Conference

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish...

KRYS : 63.09 (+0.65%)
Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to Buy

Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.

KRYS : 63.09 (+0.65%)
Krystal Biotech Reports Third Quarter 2019 Financial and Operating Results

Alignment With FDA on GMP Commercial Manufacturing Process for KB103 (Bercolagene telserpavec, "B-VEC")

KRYS : 63.09 (+0.65%)
Krystal Biotech Announces Final Update from Phase 1/2 Clinical Trial of KB103 ("bercolagene telserpavec," "B-VEC")

-- Safety data from all patients (Phase 1 and Phase 2) show that B-VEC was well tolerated with no related adverse events reported.

KRYS : 63.09 (+0.65%)
Krystal Biotech Receives Positive EMA Opinion on Orphan Designation for KB105 to Treat Patients With TGM1 Deficient Autosomal Recessive Congenital Ichthyosis

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced that the European Medicines Agency (EMA) Committee for Orphan...

KRYS : 63.09 (+0.65%)
Krystal Biotech to Present at the Cantor 2019 Global Healthcare Conference and Chardan's 3rd Annual Genetic Medicines Conference

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish...

KRYS : 63.09 (+0.65%)
Krystal Biotech Announces Granting of its First Foreign Patent and Reinforces its IP Portfolio with a New U.S. Patent

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, announced the granting of...

KRYS : 63.09 (+0.65%)
Krystal Biotech Announces Initiation of Phase 1/2 Study of KB105 in Transglutaminase-1 ("TGM1") Deficient Autosomal Recessive Congenital Ichthyosis ("ARCI")

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases, today announced the initiation of the Phase 1/2 study of KB105 in transglutaminase-1...

KRYS : 63.09 (+0.65%)
Krystal Biotech Announces Attendance at Citi's 14th Annual Biotech Conference

Krystal Biotech Inc., ("Krystal") (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish...

KRYS : 63.09 (+0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade KRYS with:

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

2nd Resistance Point 65.99
1st Resistance Point 64.54
Last Price 63.09
1st Support Level 61.79
2nd Support Level 60.49

See More

52-Week High 66.50
Last Price 63.09
Fibonacci 61.8% 47.52
Fibonacci 50% 41.66
Fibonacci 38.2% 35.80
52-Week Low 16.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar